IFNAR

IFNAR製品

• All (11)
• IFNAR阻害剤 (4)
• IFNAR抗体(1)
• IFNAR活性剤(1)
• IFNAR作動薬(2)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1537	Vadimezan (DMXAA)	Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.	Cell Chem Biol, 2025, 32(2):280-290.e14 Commun Biol, 2025, 8(1):1470 Front Pharmacol, 2025, 16:1528459
S6494	CCCP	CCCP (Carbonyl cyanide m-chlorophenyl hydrazone, Carbonyl cyanide 3-chlorophenylhydrazone), an oxidative phosphorylation inhibitor, is a protonophore mitochondrial uncoupler that increases membrane permeability to protons, leading to a disruption in the mitochondrial membrane potential.	Mol Cell, 2025, 85(7):1467-1476.e6 Life Sci, 2025, 380:123965 iScience, 2025, 28(8):112972
E2982	IFN alpha-IFNAR-IN-1 hydrochloride	IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor that inhibits the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) with IC50 value of 2-8 μM.
A2460	Anifrolumab (Anti-IFNAR1)	Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD.	Clin Transl Med, 2025, 15(5):e70323 Clin Transl Med, 2025, 15(5):e70323
S5020	Tilorone dihydrochloride	Tilorone dihydrochloride is a broad-spectrum, orally active antiviral agent that activates interferon production. It has antitumor, anti-inflammatory properties.
E0448	RO8191	RO8191 (CDM-3008, RO4948191), an imidazonaphthyridine compound, is an orally active and potent agonist of interferon (IFN) receptor. RO8191 binds directly to the IFNα/β receptor 2 (IFNAR2), activating IFN-stimulated genes (ISGs) expression and the phosphorylation of JAK/STAT signaling.
E2664	Cridanimod	Cridanimod, a low-Mw interferon-inducer (IFN-inducer), recognizes the intracellular signaling protein stimulator of interferon genes (STING), resulting in the STING-TBK1-IRF3 pathway activation and synthesis of type I IFNs (subtypes IFN-α and IFN-β).
S6727	AX-024 HCl	AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.	Cell Rep Med, 2025, S2666-3791(25)00231-9
A2053	Monalizumab (Anti-Human CD159a)	Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.	Drug Deliv, 2025, 32(1):2482195
E0448	RO8191	RO8191 (CDM-3008, RO4948191), an imidazonaphthyridine compound, is an orally active and potent agonist of interferon (IFN) receptor. RO8191 binds directly to the IFNα/β receptor 2 (IFNAR2), activating IFN-stimulated genes (ISGs) expression and the phosphorylation of JAK/STAT signaling.
E2664	Cridanimod	Cridanimod, a low-Mw interferon-inducer (IFN-inducer), recognizes the intracellular signaling protein stimulator of interferon genes (STING), resulting in the STING-TBK1-IRF3 pathway activation and synthesis of type I IFNs (subtypes IFN-α and IFN-β).
A2053	Monalizumab (Anti-Human CD159a)	Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.	Drug Deliv, 2025, 32(1):2482195
S6494	CCCP	CCCP (Carbonyl cyanide m-chlorophenyl hydrazone, Carbonyl cyanide 3-chlorophenylhydrazone), an oxidative phosphorylation inhibitor, is a protonophore mitochondrial uncoupler that increases membrane permeability to protons, leading to a disruption in the mitochondrial membrane potential.	Mol Cell, 2025, 85(7):1467-1476.e6 Life Sci, 2025, 380:123965 iScience, 2025, 28(8):112972
E2982	IFN alpha-IFNAR-IN-1 hydrochloride	IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor that inhibits the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) with IC50 value of 2-8 μM.
S6727	AX-024 HCl	AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.	Cell Rep Med, 2025, S2666-3791(25)00231-9
A2460	Anifrolumab (Anti-IFNAR1)	Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD.	Clin Transl Med, 2025, 15(5):e70323 Clin Transl Med, 2025, 15(5):e70323
S5020	Tilorone dihydrochloride	Tilorone dihydrochloride is a broad-spectrum, orally active antiviral agent that activates interferon production. It has antitumor, anti-inflammatory properties.
E0448	RO8191	RO8191 (CDM-3008, RO4948191), an imidazonaphthyridine compound, is an orally active and potent agonist of interferon (IFN) receptor. RO8191 binds directly to the IFNα/β receptor 2 (IFNAR2), activating IFN-stimulated genes (ISGs) expression and the phosphorylation of JAK/STAT signaling.
E2664	Cridanimod	Cridanimod, a low-Mw interferon-inducer (IFN-inducer), recognizes the intracellular signaling protein stimulator of interferon genes (STING), resulting in the STING-TBK1-IRF3 pathway activation and synthesis of type I IFNs (subtypes IFN-α and IFN-β).